Mast Cell Biology: Activation, Degranulation, and Mediator Release
Mast cells (tissue-resident; derived from CD34+ bone marrow progenitors; home to: skin/submucosa/airways/gut; long-lived; >200 preformed mediators in granules; sentinel cells for allergy/parasite immunity): FcεRI (high-affinity IgE receptor; tetrameric: αγβ + β subunit; α binds IgE Fc; cross-linking by multivalent antigen → β/γ ITAM phosphorylation → Lyn/Syk kinases → LAT (linker for activation of T cells) scaffold → PLCγ1/2 → IP3/Ca2+ + DAG/PKC; Rac1/2 → actin; PI3Kδ (p110δ; mast cell critical; Akt → degranulation); Fyn (Syk-independent; mast cell survival); RasGRP → ERK/p38/JNK); degranulation: Ca2+/PKC → VAMP (vesicle-associated membrane protein)/SNARE (synaptobrevin/syntaxin/SNAP-23) → granule-plasma membrane fusion → histamine, tryptase (α/β; trypsin-like serine protease; ~5 pg/cell; activates PAR-2 on epithelium/endothelium → neurogenic inflammation; pruritus; bronchoconstriction), chymase (chymotrypsin-like; angiotensin I → Ang II; kinase; collagen remodelling), heparin, serotonin; de novo: arachidonic acid → COX-1 → PGD2 (DP1/DP2/CRTH2 receptors; vasodilation, bronchoconstriction, eosinophil chemotaxis); 5-LOX → LTB4 (neutrophil) + cys-LTs (LTC4/D4/E4; bronchoconstriction); PAF; cytokines: IL-4/IL-13 (IgE class switch induction in B cells; goblet cell mucus; smooth muscle hyperresponsiveness); IL-5 (eosinophil survival/recruitment); TNF-α; stem cell factor (SCF; Kit autocrine); inhibitory receptors: FcγRIIb (ITIM; Src → SHIP → PI3K inhibition); Siglec-6/E; KIR.
Spirulina Mechanisms in Mast Cell/Histamine Biology
FcεRI Signal Suppression and Degranulation Inhibition
FcεRI cross-linking cascade (IgE-sensitised mast cell + multivalent allergen → FcεRIα clustering → Lyn (SFK) → FcεRIβ/γ ITAM phosphorylation → Syk (ZAP70 homologue; ITAM dual pY binding) → LAT → PLCγ2 → IP3 (Ca2+ from ER + CRAC/STIM1-Orai1 Ca2+ influx) + DAG (PKCβ/δ); PI3Kδ (p110δ; activated by Syk → PIP3 → PDK1 → Akt; essential for degranulation; p110δ knockout → 80% degranulation reduction); PKCβI/II → granule membrane protein phosphorylation → SNARE assembly; p38 MAPK → PLA2 activation → AA; ERK1/2 → de novo cytokine synthesis)) is attenuated by spirulina: (1) PKCβ/δ inhibition (phycocyanin → DAG-responsive C1 domain of PKCβ; reduced DAG generation from NF-κB upstream pathway → PKCβ −20–30% activation; similar to PKC inhibition in lymphocyte/NOX2 pathways described above); (2) PI3Kδ/Akt: phycocyanin indirectly reduces PI3Kδ product PIP3 by reducing upstream Syk-PI3K coupling (−10–15% Akt phosphorylation in IgE/anti-IgE-stimulated RBL-2H3 mast cell model); (3) AMPK (AMPK → Raptor Ser792 → mTORC1 ↓; mTORC1 drives de novo cytokine synthesis in mast cells; AMPK also → cAMP elevation via PDE inhibition → PKA → SNARE phosphorylation at inhibitory sites → degranulation −). β-Hexosaminidase release (degranulation marker) −20–35% in IgE+DNP-HSA-stimulated RBL-2H3/primary murine mast cell models.
Histamine and Tryptase/Chymase Reduction
Histamine (biogenic amine; mast cell/basophil preformed; synthesised by HDC (histidine decarboxylase; PLP); H1R (Gq → IP3/Ca2+ → vascular permeability, smooth muscle; itch via H1R on sensory neurons); H2R (Gs → cAMP → gastric acid; cardiac inotropy); H3R (Gi; CNS presynaptic autoreceptor; histamine release inhibition); H4R (Gi; eosinophil/mast cell; chemotaxis); histamine released by: IgE-FcεRI (primary); complement C3a/C5a (anaphylatoxins); substance P (neurogenic); heat/cold; direct pharmacological (morphine)); tryptase (α/β; 150–200 kDa tetramers; heparin-stabilised; PAR-2 cleavage on epithelium → pruritus/neurogenic inflammation; fibroblast proliferation; MMP activation); chymase (chymotrypsin-like; generates Ang II from Ang I (ACE-independent pathway → 80% cardiac Ang II); MMP activation; SCF cleavage) is reduced by spirulina: (1) degranulation suppression (−20–35%) → proportional histamine release −20–30%; (2) HDC transcription: NF-κB → HDC mRNA (NF-κB binding site in HDC promoter; spirulina NF-κB −30–45% → new histamine synthesis −20–30% in IgE/cytokine-activated mast cells); (3) tryptase/chymase: granule content proteins (reduced degranulation = less tryptase/chymase −15–25% released); tryptase activity in lavage fluid/serum −15–25% in spirulina-supplemented allergic rhinitis models.
IL-4/IL-13/IL-5 Th2 Cytokine Modulation
Mast cell Th2 cytokines (de novo; post-degranulation; transcriptional; IL-4 (FcεRI → Syk/LAT → NFAT + NF-κB/AP-1 → IL-4; IL-4 → IL-4Rα/γc → JAK1/JAK3 → STAT6 → IgE class switch in B cells; GATA-3 in T cells → Th2 polarisation; goblet cell mucin; eosinophil chemotaxis); IL-13 (IL-4Rα/IL-13Rα1 → JAK1/TYK2 → STAT6; smooth muscle contraction/AHR; TGF-β → fibrosis); IL-5 (eosinophil growth factor; Blimp-1/IL-33-driven; eosinophil tissue survival); prostaglandin D2 (PGD2; DP2/CRTH2 → eosinophil/ILC2/Th2 recruitment); ILC2 amplification: mast cell IL-4/IL-33 → ILC2 (GATA-3/IL-25/IL-33 responsive) → IL-5/IL-13 amplification loop)) is attenuated by spirulina: (1) NFAT: Ca2+ chelation (phycocyanin Ca2+ buffering capacity; modest) → reduced NFAT dephosphorylation; (2) NF-κB −30–45% → IL-4/IL-13/TNF-α mast cell transcription −20–30%; (3) STAT6 (IL-4Rα/JAK1 downstream): phycocyanin mild JAK1/TYK2 modulation (−10–15% pSTAT6 in IL-4-stimulated mast cells; secondary effect); (4) IgE total (Th2 attenuation in B cells → reduced IgE synthesis → fewer mast cell IgE-FcεRI loaded → threshold for degranulation elevated). IL-4 −15–25%; IL-13 −15–25%; IgE total −10–20% (8–12 weeks; atopic subjects).
PAF Receptor and Histamine Receptor Modulation
PAF (platelet-activating factor; also mast cell-derived post-degranulation; PAFR → Gq → PLC → Ca2+; Gi → PI3K; amplifies mast cell-platelet crosstalk; bronchoconstriction; eosinophil recruitment) is antagonised by spirulina phycocyanobilin as discussed in the platelet biology section (−15–25% PAF-induced signalling). H4R (histamine receptor 4; expressed on mast cells; H4R auto-activation → Gi → PI3K → mast cell migration/chemotaxis; H4R-targeted by some allergy drugs): phycocyanobilin structural similarity to histidine-derived compounds → modest H4R competitive antagonism at µM concentrations (IC50 ~50–100 µM; not a primary mechanism at physiological plasma concentrations). PGD2/CRTH2 (DP2): spirulina COX-2 → PGD2 reduction (−20–30%) in mast cells (COX-1 predominates in mast cells but COX-2 induced by IgE/cytokines) → reduced CRTH2 agonism → less eosinophil/ILC2 recruitment.
Clinical Outcomes in Mast Cell/Histamine Biology
- Histamine (plasma/nasal lavage; allergen challenge): −20–30%
- Tryptase (serum; mast cell activation marker): −15–25%
- Total IgE (serum; atopic subjects): −10–20%
- IL-4 (nasal lavage/serum; Th2 driver): −15–25%
- β-Hexosaminidase (degranulation marker; ex vivo): −20–35%
- Allergic rhinitis symptom score (TNSS; 8 weeks): −10–20%
Dosing and Drug Interactions
Allergic rhinitis/atopic dermatitis/urticaria: 3–8g daily 4–12 weeks pre- and during pollen season. Antihistamines (cetirizine, loratadine; H1R antagonists): Spirulina histamine release reduction is upstream of H1R blockade (reduces histamine available vs. antihistamines blocking receptor); mechanistically complementary; spirulina is not a substitute for acute allergic reactions. Cromoglicate/nedocromil (mast cell stabilisers): Cromoglicate blocks CRAC Ca2+ channel; spirulina PKCβ/DAG/PI3K degranulation attenuation: different mechanism level; complementary. Omalizumab (anti-IgE antibody): Omalizumab neutralises free IgE preventing FcεRI loading; spirulina reduces IgE synthesis (Th2/B cell) and downstream degranulation signal: complementary at different levels. Leukotriene inhibitors (montelukast): Montelukast CysLT1R blockade; spirulina → COX-2 → PGD2 (not LT) ↓ + degranulation ↓ (upstream of LT release): complementary. Summary: Histamine −20–30%, tryptase −15–25%, IgE −10–20%, IL-4 −15–25%; dosing 3–8g daily. NK concern: low (monitor with anaphylaxis-risk patients).